A phase 3 trial of bevacizumab in ovarian cancer.

J Perren, Timothy; Marie Swart, Ann; Pfisterer, Jacobus; A Ledermann, Jonathan; Pujade-Lauraine, Eric; Kristensen, Gunnar; S Carey, Mark; Beale, Philip; Cervantes, Andrés; Kurzeder, Christian; du Bois, Andreas; Sehouli, Jalid; Kimmig, Rainer; Stähle, Anne; Collinson, Fiona; Essapen, Sharadah; Gourley, Charlie; Lortholary, Alain; Selle, Frédéric; R Mirza, Mansoor; Leminen, Arto; Plante, Marie; Stark, Dan; Qian, Wendi; K B Parmar, Mahesh; M Oza, Amit; Investigators, ICON7

doi:10.1056/NEJMoa1103799

Public

A phase 3 trial of bevacizumab in ovarian cancer.

Shared by NobleBlocks on Dec 29, 2011 • 12:00 AM UTC

Authors:

Timothy J Perren

Ann Marie Swart

Jacobus Pfisterer

Abstract

BACKGROUND: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. METHODS: We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!